Naringenin decreases mitochondrial function. by Lauren A. Eanes (20995499)

Naringenin decreases total cell viability. by Lauren A. Eanes (20995499)

Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

Experimental validation revealed that ACADSB and ACADM decreased in patients with UC. by Hongliang Chen (538815)

Knock-down of DYRK1A decreases HBV RNAs levels in HBV-infected dHepaRG cells. by Florentin Pastor (19852287)

Subjects: “…chronically infected patients…”

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Subjects:

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

“…Their median baseline variabilities of respiratory rate and tidal volume were 0.19 (IQR: 0.16–0.25) and 0.23 (0.19–0.34), respectively. While mean respiratory rate was not affected, midazolam resulted in a significant decrease in both VRR (ß = −0.071, 95% CI: −0.120 to −0.021) and VTV (ß = −0.117, 95% CI: −0.170 to −0.062). …”

<i>RTTN</i>-mutated organoids exhibit decreased proliferation and increased cell death at early stages. by Justine Guguin (9088672)

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

MAP3K1, MAPK11, and PPP2R1A knockdown decreased ECM internalisation. by Montserrat Llanses Martinez (17797522)

Decreased production of antiviral factors in patients infected with SARS-CoV-2 due to reduced TLR7 expression by Julia Cataldo Lima (22811497)

“…A decrease in pattern recognition receptors (PRRs) was also observed at both the gene and protein levels. …”

Decreased synthesis of VCAM-1, tubulin and dynein proteins in the heart of mice stimulated with EVs (green) or ICs (blue). by Alberto Cornet-Gomez (10676133)

“…<p>Confocal microscopy images of heart sections incubated with specific antibodies against VCAM-1 <b>(A)</b>, tubulin <b>(B)</b> and dynein <b>(C)</b> showed a decrease in fluorescence signals in samples from the EVs and ICs groups. …”

A summary of the included study characteristics. by Zahra Tajik (20752452)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Real-world mepolizumab treatment in patients with severe asthma decreased exacerbations, oral corticosteroid use, and healthcare resource utilization and costs over 4 years: a retrospective analysis by Wendy C. Moore (10682686)

“…</p> <p>Among 189 eligible patients, mean asthma exacerbation rate (AER) declined progressively from baseline during follow-up: AER decreased by 53.8% at Year 1 and 73.8% by Year 4 (<i>p</i> < 0.001). …”

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects: